title: Linagliptin. Avoid gliptins!
mesh_terms: D015415:Biomarkers / Q000097:blood; D048909:Diabetes Complications / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D004342:Drug Hypersensitivity / Q000209:etiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007107:Immune System / Q000187:drug effects; D000069476:Linagliptin; D010195:Pancreatitis / Q000139:chemically induced; D018579:Patient Selection; D011687:Purines / Q000009:adverse effects* / Q000493:pharmacokinetics; D011799:Quinazolines / Q000009:adverse effects* / Q000493:pharmacokinetics; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D000069476:Linagliptin; D011687:Purines; D011799:Quinazolines; C517652:hemoglobin A1c protein, human